Harada Kei, Fujikawa Takahisa, Uemoto Yusuke, Aibe Yuki
Surgery, Kokura Memorial Hospital, Kitakyushu, JPN.
Gastroenterology, Kokura Memorial Hospital, Kitakyushu, JPN.
Cureus. 2024 Feb 11;16(2):e53997. doi: 10.7759/cureus.53997. eCollection 2024 Feb.
Multiple hepatocellular carcinomas (HCCs) are currently being treated with multimodal therapy that includes liver resection and local therapy. Although the necessity of multimodal therapy for multiple HCCs is evident, treating them is extremely difficult due to the complex nature of multiple HCCs and the frequent occurrence of underlying liver damage. We encountered a case in which long-term tumor control was achieved through multidisciplinary treatment, including atezolizumab plus bevacizumab combination biological therapy. As in the current case, less-invasive surgical resection combined with radiofrequency ablation after a combination of biological therapy may be one of the preferred options for the treatment of initially unresectable multiple HCCs.
目前,多灶性肝细胞癌(HCC)采用包括肝切除和局部治疗在内的多模式疗法进行治疗。尽管多模式疗法对多灶性HCC的必要性显而易见,但由于多灶性HCC的复杂性和潜在肝损伤的频繁发生,治疗极为困难。我们遇到了一例通过多学科治疗实现长期肿瘤控制的病例,包括阿替利珠单抗联合贝伐单抗的生物联合疗法。正如当前病例一样,在生物联合治疗后,采用微创性手术切除联合射频消融可能是治疗初始不可切除的多灶性HCC的首选方案之一。